Ph+ ALL: drawing strength from a benign past.

Publication Year:

2015

Authors:

Markus Muschen

PubMed ID:

25953975

Funding Grants:

Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication

Public Summary:

In this issue of Blood, Mallampati et al report on the discovery of a new mechanism of tyrosine kinase inhibitor (TKI) resistance, which is mediated through TKI-mediated priming of mesenchymal stem cells (MSCs) in the bone marrow (BM).

Scientific Abstract:

In this issue of Blood, Mallampati et al report on the discovery of a new mechanism of tyrosine kinase inhibitor (TKI) resistance, which is mediated through TKI-mediated priming of mesenchymal stem cells (MSCs) in the bone marrow (BM).